HK1072539A1 - Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover - Google Patents

Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover

Info

Publication number
HK1072539A1
HK1072539A1 HK05105175A HK05105175A HK1072539A1 HK 1072539 A1 HK1072539 A1 HK 1072539A1 HK 05105175 A HK05105175 A HK 05105175A HK 05105175 A HK05105175 A HK 05105175A HK 1072539 A1 HK1072539 A1 HK 1072539A1
Authority
HK
Hong Kong
Prior art keywords
bisphosphonates
treatment
abnormally increased
conditings
medicament
Prior art date
Application number
HK05105175A
Other languages
English (en)
Inventor
Zebulun D Horowitz
Peter C Richardson
Ulrich Trechsel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1072539A1 publication Critical patent/HK1072539A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05105175A 2000-06-20 2005-06-22 Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover HK1072539A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59713500A 2000-06-20 2000-06-20
US26768901P 2001-02-09 2001-02-09
PCT/EP2001/006850 WO2001097788A2 (en) 2000-06-20 2001-06-18 Method of administering bisphosphonates

Publications (1)

Publication Number Publication Date
HK1072539A1 true HK1072539A1 (en) 2005-09-02

Family

ID=26952565

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105175A HK1072539A1 (en) 2000-06-20 2005-06-22 Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover

Country Status (25)

Country Link
US (1) US8052987B2 (xx)
EP (1) EP1296689B3 (xx)
JP (2) JP4722375B2 (xx)
KR (1) KR100864743B1 (xx)
CN (1) CN1272013C (xx)
AT (1) ATE304856T1 (xx)
AU (2) AU7410901A (xx)
BR (1) BR0111806A (xx)
CA (1) CA2410201C (xx)
CY (2) CY1113740T1 (xx)
CZ (1) CZ301972B6 (xx)
DE (1) DE60113537T3 (xx)
DK (1) DK1296689T3 (xx)
ES (2) ES2247123T7 (xx)
HK (1) HK1072539A1 (xx)
HU (1) HU228400B1 (xx)
IL (2) IL153229A0 (xx)
MX (1) MXPA02012682A (xx)
NO (1) NO330459B1 (xx)
NZ (1) NZ523086A (xx)
PL (1) PL203087B1 (xx)
PT (1) PT1591122E (xx)
SK (1) SK287278B6 (xx)
TW (1) TWI289451B (xx)
WO (1) WO2001097788A2 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
KR100864743B1 (ko) 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
NZ528659A (en) * 2001-04-03 2005-02-25 Royal Alexandra Hosp Children A drug for use in bone grafting
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
ATE376444T1 (de) * 2002-05-10 2007-11-15 Hoffmann La Roche Ibandronsäure zur behandlung und vorbeugung von osteoporose
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
CN1705485A (zh) * 2002-10-15 2005-12-07 诺瓦提斯公司 施用双膦酸类化合物的方法
BR0309691A (pt) 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
EP1709968A1 (en) * 2004-01-30 2006-10-11 Astellas Pharma Inc. P2x receptor inhibitor
JP4559431B2 (ja) * 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
KR20070085874A (ko) 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
US7709508B2 (en) 2004-12-09 2010-05-04 Merck Sharp & Dohme Estrogen receptor modulators
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
WO2007124274A1 (en) * 2006-04-21 2007-11-01 The Uab Research Foundation Treating neoplasms
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100068211A1 (en) * 2008-02-08 2010-03-18 Bateman Ted A Use of antiresorptive compounds to prevent ionizing radiation-induced activation of osteoclasts and resulting bone loss
US8999383B2 (en) * 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
CN105920023A (zh) 2009-09-01 2016-09-07 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
EP2780021A4 (en) 2011-11-16 2015-08-05 Univ Duke BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE
CN103623465B (zh) * 2013-11-21 2015-12-30 彭江 一种可局部调节成破骨活性的组织工程骨支架及制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR20180115979A (ko) 2017-04-14 2018-10-24 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물
GB201716716D0 (en) 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理
KR102049233B1 (ko) * 2019-01-14 2019-11-28 연세대학교 산학협력단 비스포스포네이트를 포함하는 만성 이식신 기능부전 예방 또는 치료용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594329A (en) * 1897-11-23 Socket or collet
DE3232959A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Substituierte benzolsulfonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0381296B1 (en) 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
JPH07502507A (ja) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
WO1994000129A1 (en) 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5366965A (en) 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
KR970705400A (ko) 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
WO1996007418A1 (en) 1994-09-09 1996-03-14 The Procter & Gamble Company Phosphonates and parathyroid hormone for osteoporosis
ES2239774T3 (es) 1995-09-29 2005-10-01 Novartis Ag Metodo de tratamiento de la enfermedad navicular en caballos.
US5735810A (en) 1996-06-14 1998-04-07 Becton Dickinson And Company Device for the iontophoretic administration of bisphosphonates
US5730715A (en) 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
SG109478A1 (en) 1997-07-22 2005-03-30 Merck & Co Inc Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
GB2336311A (en) 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
CA2308532C (en) 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
WO2000071104A2 (en) * 1999-05-21 2000-11-30 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
US20010044427A1 (en) 1999-12-20 2001-11-22 Sidney Mazel Pharmaceutical kit
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
KR100864743B1 (ko) 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법

Also Published As

Publication number Publication date
NO20026117D0 (no) 2002-12-19
ES2247123T3 (es) 2006-03-01
DE60113537T2 (de) 2006-06-29
EP1296689A2 (en) 2003-04-02
JP4722375B2 (ja) 2011-07-13
CY2013011I2 (el) 2015-08-05
BR0111806A (pt) 2003-05-20
HUP0301164A3 (en) 2005-11-28
NO20026117L (no) 2002-12-19
TWI289451B (en) 2007-11-11
JP5005188B2 (ja) 2012-08-22
CZ20024134A3 (cs) 2003-06-18
CY1113740T1 (el) 2015-08-05
US8052987B2 (en) 2011-11-08
EP1296689B3 (en) 2013-02-13
PL203087B1 (pl) 2009-08-31
CZ301972B6 (cs) 2010-08-18
JP2003535889A (ja) 2003-12-02
HUP0301164A2 (hu) 2003-08-28
PL358224A1 (en) 2004-08-09
SK18082002A3 (sk) 2003-08-05
US20030181421A1 (en) 2003-09-25
CA2410201A1 (en) 2001-12-27
HU228400B1 (en) 2013-03-28
CN1272013C (zh) 2006-08-30
CN1620300A (zh) 2005-05-25
SK287278B6 (sk) 2010-05-07
EP1296689B1 (en) 2005-09-21
AU2001274109B2 (en) 2004-12-23
DE60113537T3 (de) 2013-05-29
DK1296689T3 (da) 2005-11-28
CA2410201C (en) 2010-10-26
DE60113537D1 (de) 2006-02-02
WO2001097788A3 (en) 2002-06-27
NO330459B1 (no) 2011-04-18
KR20030015283A (ko) 2003-02-20
ES2247123T7 (es) 2013-03-01
PT1591122E (pt) 2012-12-12
JP2005247873A (ja) 2005-09-15
WO2001097788A2 (en) 2001-12-27
ATE304856T1 (de) 2005-10-15
KR100864743B1 (ko) 2008-10-22
CY2013011I1 (el) 2015-08-05
MXPA02012682A (es) 2003-04-25
IL153229A0 (en) 2003-07-06
AU7410901A (en) 2002-01-02
NZ523086A (en) 2007-07-27
IL153229A (en) 2007-07-24
ES2394211T3 (es) 2013-01-23

Similar Documents

Publication Publication Date Title
HK1072539A1 (en) Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover
NZ527157A (en) Compositions for delivering bisphosphonates
MY140080A (en) Treatment and prevention of osteoporosis
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
DE69528525D1 (de) Feuchtgranulierung formulierung für bisphosphonsäuren
AU1706102A (en) Use of bisphosphonates for pain treatment
NZ514478A (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20210617